Diabetes
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wang, Z.
Right arrow Articles by Levi, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wang, Z.
Right arrow Articles by Levi, M.
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Diabetes 54:2328-2335, 2005
© 2005 by the American Diabetes Association, Inc.

Regulation of Renal Lipid Metabolism, Lipid Accumulation, and Glomerulosclerosis in FVBdb/db Mice With Type 2 Diabetes

Zhuowei Wang1, Tao Jiang1, Jinping Li1, Gregory Proctor1, James L. McManaman2, Scott Lucia3, Streamson Chua4, and Moshe Levi1

1 Division of Renal Diseases and Hypertension, Department of Medicine, University of Colorado Health Sciences Center, Denver, Colorado
2 Division of Basic Reproductive Sciences, Department of Obstetrics and Gynecology, University of Colorado Health Sciences Center, Denver, Colorado
3 Department of Pathology, University of Colorado Health Sciences Center, Denver, Colorado
4 Division of Molecular Genetics and New York Obesity Research Center, Department of Pediatrics, Columbia University, New York


   ABSTRACT
TOP
 ABSTRACT
RESEARCH DESIGN AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Diabetic kidney disease has been associated with the presence of lipid deposits, but the mechanisms for the lipid accumulation have not been fully determined. In the present study, we found that db/db mice on the FVB genetic background with loss-of-function mutation of the leptin receptor (FVB-Leprdb mice or FVBdb/db) develop severe diabetic nephropathy, including glomerulosclerosis, tubulointerstitial fibrosis, increased expression of type IV collagen and fibronectin, and proteinuria, which is associated with increased renal mRNA abundance of transforming growth factor-ß, plasminogen activator inhibitor-1, and vascular endothelial growth factor. Electron microscopy demonstrates increases in glomerular basement membrane thickness and foot process (podocyte) length. We found that there is a marked increase in neutral lipid deposits in glomeruli and tubules by oil red O staining and biochemical analysis for cholesterol and triglycerides. We also detected a significant increase in the renal expression of adipocyte differentiation-related protein (adipophilin), a marker of cytoplasmic lipid droplets. We examined the expression of sterol regulatory element–binding protein (SREBP)-1 and -2, transcriptional factors that play an important role in the regulation of fatty acid, triglyceride, and cholesterol synthesis. We found significant increases in SREBP-1 and -2 protein levels in nuclear extracts from the kidneys of FVBdb/db mice, with increases in the mRNA abundance of acetyl-CoA carboxylase, fatty acid synthase, and 3-hydroxy-3-methylglutaryl-CoA reductase, which mediates the increase in renal triglyceride and cholesterol content. Our results indicate that in FVBdb/db mice, renal triglyceride and cholesterol accumulation is mediated by increased activity of SREBP-1 and -2. Based on our previous results with transgenic mice overexpressing SREBP-1 in the kidney, we propose that increased expression of SREBPs plays an important role in causing renal lipid accumulation, glomerulosclerosis, tubulointerstitial fibrosis, and proteinuria in mice with type 2 diabetes.

Address correspondence and reprint requests to Moshe Levi, MD, 4200 E. 9th Ave., Division of Renal Diseases and Hypertension, University of Colorado Health Sciences Center, Denver, Colorado 80262. E-mail: moshe.levi{at}uchsc.edu

Abbreviations: ABCA-1, ATP-binding cassette transporter-1; ACC, acetyl-CoA carboxylase; ACO, acyl-CoA oxidase; ADRP, adipocyte differentiation-related protein; FAS, fatty acid synthase; HMG, 3-hydroxy-3-methylglutaryl; LXR, liver X receptor; PAI-1, plasminogen activator inhibitor-1; PPAR-{alpha}, peroxisome proliferator–activated receptor-{alpha}; SREBP, sterol regulatory element–binding protein;; TGF-ß, transforming growth factor-ß; VEGF, vascular endothelial growth factor

There is growing evidence that abnormal lipid metabolism and renal accumulation of lipids play a role in the pathogenesis of diabetic nephropathy (1–4). Since the description by Kimmelstiel and Wilson (5) of nodular glomerulosclerosis and presence of lipid deposits in the diabetic kidney, several investigators have shown the presence of lipid accumulation in the kidneys of diabetic humans and experimental animals, and they have proposed that the lipids may play an important role in the pathogenesis of diabetic kidney disease (4,6,7). The major assumption has been that these lipid deposits originate solely from increased levels of serum lipids. Whether the accumulation of lipids per se may mediate diabetic renal disease is supported by increased abundance of transforming growth factor-ß (TGF-ß) and vascular endothelial growth factor (VEGF) and changes of diabetic glomerulosclerosis and proteinuria in sterol regulatory element–binding protein-1a (SREBP-1a) transgenic mice with increased renal triglyceride content (4).

The SREBPs have been described as master regulators of both fatty acid and cholesterol metabolism (8–11). Three SREBP isoforms have been identified and characterized, SREBP-1a, -1c, and -2 (8). Studies in transgenic mice overexpressing each of the three SREBP isoforms in the liver have indicated that SREBP-1a and -1c isoforms play a preferential role in fatty acid synthesis, whereas SREBP-2 plays a preferential role in cholesterol synthesis (12,13). In a recent study, we found that in a rat model of type 1 diabetes, there is increased renal accumulation of lipids, which is mediated by increased expression of SREBP-1 (4). In cultured mesangial cells, high-glucose medium also stimulates increased expression of SREBP-1 (4). In SREBP-1a transgenic mice, in the absence of any changes in serum glucose or serum lipids, there is increased accumulation of triglyceride and cholesterol in the kidney, which is associated with increased expression of TGF-ß, VEGF, and the extracellular matrix proteins type IV collagen and fibronectin, resulting in glomerular hypertrophy, glomerulosclerosis, and proteinuria (4). This study indicates that increased expression of SREBP-1 plays an important role in the pathogenesis of diabetic kidney disease in type 1 diabetes. However, whether SREBPs also play a role in the regulation of renal lipid metabolism and the development of diabetic nephropathy in type 2 diabetes has not been determined.

Three lines of evidence suggest that altered lipid metabolism is associated with diabetic and nondiabetic renal disease. First, there are a number of genetic abnormalities of lipid metabolism in humans and experimental animals, including Fabry’s disease (14), lecithin cholesterol acyltransferase deficiency (15), type IA glycogen storage disease (von Gierke’s disease) (16), genetic and acquired lipodystrophy (17,18), ATP-binding cassette transporter-1 (ABCA-1) knockout mice (a murine model of Tangiers disease) and familial HDL deficiency, with defects in ABCA-1 and HDL-mediated reverse cholesterol transport (19,20), and ApoE knockout mice, where abnormalities in serum and tissue lipids, including renal lipid composition, are associated with glomerular disease and proteinuria (21,22). Second, increases in serum lipids have been associated with a faster decline of renal function (23,24). Third, there is also increasing evidence that inhibition of cholesterol synthesis by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors (statins), inhibition of triglyceride synthesis by peroxisome proliferator–activated receptor-{alpha} (PPAR-{alpha}) agonists (fibrates), or a decrease in LDL achieved by LDL apheresis protect against diabetic and nondiabetic renal disease (25–27). A meta-analysis of several small-scale interventional studies in diabetic and nondiabetic human subjects with glomerulosclerosis and proteinuria in fact indicate that long-term treatment with statins and/or fibrates significantly prevents the decline in glomerular filtration rate (25).

A recent study of obese db/db mice of the FVBdb/db congenic strain demonstrated the presence of long-term hyperglycemia that is primarily caused by severe insulin resistance. The hyperglycemia of the obese mice in the fed state persists, despite escalating secretion of insulin and a massive increase of pancreatic ß-cells (28). Obese FVB mice show evidence of mesangial matrix expansion, a hallmark of diabetic nephropathy. Therefore, FVBdb/db is an excellent animal model of type 2 diabetes for studying the pathogenesis of diabetic kidney disease. We tested our hypothesis that increased expression of SREBPs plays an important role in renal lipid accumulation and the development of diabetic nephropathy in this type 2 diabetic animal model.


   RESEARCH DESIGN AND METHODS
TOP
 ABSTRACT
 RESEARCH DESIGN AND METHODS
RESULTS
 DISCUSSION
 REFERENCES
 
A total of 12 female FVBdb/db mice and 12 control mice genotyped to be wild type at the db locus at age 3 months were transferred from Columbia University to the animal facility at the Denver Veterans Affairs Medical System. The mice had been maintained on a 12-h light/dark cycle and fed standard rodent chow (Rodent Chow 5015; Ralston Purina, St. Louis, MO) ad libitum for 3 more months until they were killed. The experimental animal committee of the University of Colorado Health Sciences Center and the Veterans Affairs Medical Center at Denver gave approval for all experiments involving animals.

Spot urine samples for measurement of albumin and creatinine were obtained on all mice. After the urine collection, eight mice in each age-group were killed by intraperitoneal injection of pentobarbital (Abbott Laboratories, Chicago, IL). We obtained 0.5 ml of blood in a heparinized syringe via heart puncture at the time of death. In addition, four mice in each age-group underwent in vivo perfusion fixation of the kidneys, and the kidneys were then processed for histological stains, immunofluorescence microscopy, and electron microscopy, as described below.

Urine chemistries.
Urine albumin concentration was determined by competitive enzyme-linked immunosorbent assay via an Albuwell M kit (Exocell, Philadelphia, PA). Urine creatinine concentration was determined by Jaffe’s reaction of alkaline picrate with creatinine via a Creatinine Companion kit (Exocell). Results were expressed as the urine albumin-to-creatinine ratio (µg/mg).

Homogenate and nuclei isolation.
Kidneys were homogenized at 4°C in homogenization buffer, as previously described (4). Nuclear extracts were prepared according to the method of Morooka et al. (29). The protein concentration was determined by the method of Lowry et al. (30). The nuclear extracts were stored at –80°C.

Protein electrophoresis and Western blotting.
Protein samples were subjected to SDS-PAGE (10% wt/vol) and then transferred to nitrocellulose membranes. Membranes were blocked in 5% powdered milk in Tris-buffered saline with Tween (0.2% Tween 20 in 1x Tris-buffered saline) and incubated with 1) anti–SREBP-1, 2) anti–SREBP-2 (1:1,000 dilution; BD Biosciences, Pharmingen, San Jose, CA.), and 3) adipophilin (adipocyte differentiation-related protein [ADRP]; 1:2000; Roche Biochemicals, Indianapolis, IN) followed by horseradish peroxidase–labeled anti-rabbit IgG (1:5,000 dilution; Molecular Probes, Eugene, OR). Next, samples were washed four times with 1x Tris-buffered saline and then developed using a chemiluminescence detection system (Pierce Biotechnology, Rockford, IL.). The signals were quantified in a Phosphor Imager with chemiluminescence detector and densitometry software (Bio-Rad Laboratories, Hercules, CA).

Lipid extraction and analysis.
Total lipid was extracted from kidney cortex by the method of Bligh and Dyer (31). Total cholesterol was analyzed using a cholesterol CII kit (Wako Chemicals, Richmond, VA). Triglycerides were determined by the L Type TG H kit. (Wako).

Total RNA extraction and real-time PCR.
Total RNA was extracted according to Trizol protocol (Invitrogen Life Technologies, Carlsbad, CA). Then, 2 µg of total RNA was subject to DNase digestion, using an iScript cDNA Synthesis Kit (Bio-Rad Laboratories) to make cDNA. iQSYBR Green Supermix (Bio-Rad Laboratories) was used for real-time PCR according to manufacturer’s instructions. Primers used are as follows: cyclophilin (sense: TGGAGAGCACCAAGACAGACA; antisense: TGCCGGAGTCGACAATGAT), acetyl-CoA carboxylase (ACC; sense: CCCAGCAGAATAAAGCTACTTTGG; antisense: TCCTTTTGTGCAACTAGGAACGT), fatty acid synthase (FAS; sense: CCTGGATAGCATTCCGAACCT; antisense: AGCACATCTCGAAGGCTACACA), HMG-CoA reductase (sense: AGCCGAAGCAGCACATGAT; antisense: CTTGTGGAATGCCTTGTGATTG), plasminogen activator inhibitor-1 (PAI-1; sense: GGACACCCTCAGCATGTTCA; antisense: TCTGATGAGTTCAGCATCCAAGAT), PPAR-{alpha} (sense: CTGCAGAGCAACCATCCAGAT; antisense: GCCGAAGGTCCACCATTTT), TGF-ß (sense: TAGTAGACGATGGGCAGTGG; antisense: TAGTAGACGATGGGCAGTGG), ABCA-1 (sense: CGTTTCCGGGAAGTGTCCTA; antisense: GCTAGAGATGACAAGGAGGATGGA), VEGF (sense: AACGATGAAGCCCTGGAGTG; antisense: TGAGAGGTCTGGTTCCCGA), LDL receptor (sense: GAAGTCGACACTGTACTGACCACC; antisense: CTCCTCATTCCCTCTGAAAGCCAT), acyl-CoA oxidase (ACO; sense: GGCCAACTATGGTGGACATCA; antisense: ACCAATCTGGCTGCACGAA), and liver X receptor (LXR; sense: TTGCACCCGACCCTCAGA; antisense: ACGATGGCCAGCTCAGTAAAG).

Perfusion fixation of mouse kidney.
Mice were anesthetized and perfused at a pressure of 180 mmHg through the abdominal aorta, as previously described (4).

Periodic acid Schiff staining, oil red O staining, and immunofluorescence microscopy.
Paraffin sections were stained for periodic acid Schiff. Frozen sections were used for oil red O staining to determine the renal accumulation of neutral fats. The stained kidney sections were imaged with an Olympus microscope and scored semiquantitatively in a blinded manner by the renal pathologist (S.L.).

Immunofluorescence microscopy for type IV collagen and fibronectin were performed as previously described (4). The kidney sections were then imaged with a laser scanning confocal microscope (Zeiss LSM 510).

For adipophilin (ADRP) imaging, paraffin-embedded sections were used, and ADRP was detected by binding to antibodies to ADRP (1:500; Roche Biochemicals) (32,33) in conjunction with Alexa-488–labeled (Molecular Probes) secondary antibodies. Lipid droplets and nuclei were stained with Nile red and 4',6-diamidino-2-phenylindol, as described previously (32).

Electron microscopy.
Perfusion-fixed tissue was immediately postfixed in 1% buffered osmium tetroxide. The sample was dehydrated in a graded series of ethanol and embedded in an epoxy resin. Tissue was surveyed with a series of 1-µm sections for a representative sample. The selected specimens were thin sectioned, viewed, and photographed with an electron microscope (model 201; Phillips Electron Optics, Mahwah, NJ). The sections were read by the renal pathologist (S.L.) for determination of basement membrane thickness and podocyte morphology.

Statistical analysis.
SPSS 11.0 for Windows was used for statistical analysis. The results were expressed as the means ± SE. The statistical significance of differences was assessed by one-way ANOVA.


   RESULTS
TOP
 ABSTRACT
 RESEARCH DESIGN AND METHODS
 RESULTS
DISCUSSION
 REFERENCES
 
FVBdb/db mice are obese and hyperlipidemic.
As shown in Table 1, at the age of 6 months, FVBdb/db mice are much heavier than their lean littermates in body, kidney, and liver weight (P < 0.01). Because almost all of the increased mass of the db/db mice is caused by triglyceride accumulation rather than an overall increase in all body compartments, the increased kidney and liver weights represent significant increases in organ weights relative to fat-free mass. Plasma cholesterol and triglyceride levels were much higher in FVB-Leprdb mice than control mice.


View this table:
[in this window]
[in a new window]

  		TABLE 1 Metabolic data for lean and FVBdb/db mice

 
FVBdb/db mice develop glomerulosclerosis, tubulointerstitial fibrosis, and proteinuria.
Periodic acid Schiff staining clearly reveals mesangial expansion, increased matrix protein accumulation, and tubulointerstitial fibrosis in FVBdb/db mice (Figs. 1B, C, and D) when compared with age- and sex-matched control mice (Fig. 1A). Immunofluorescence microscopy with anti-fibronectin and anti–type IV collagen (Fig. 2) antibodies indicates increased intensity of immunofluorescence in the glomeruli and tubulointerstitial cells in FVBdb/db mice, indicating accumulation of extracellular matrix proteins and glomerulosclerosis and tubulointerstitial fibrosis. Furthermore, electron microscopy shows increased glomerular basement membrane thickness and podocyte foot process length in FVBdb/db mice (Figs. 3A–D). Increased urine-to-albumin ratio usually is an early indication of diabetic nephropathy. This ratio is significantly elevated in FVBdb/db mice when compared with lean mice (Table 1).


Figure 1
View larger version (134K):
[in this window]
[in a new window]

  		FIG. 1. Periodic acid Schiff staining of in vivo–perfused and paraffin-embedded kidney sections (100x magnification). A: Lean control mice. B–D: FVBdb/db mice showing glomerulosclerosis in B, presence of a proteinaceous cast in C, and tubulointerstitial fibrosis in D. n = 4 mice in each experimental group.

 

Figure 2
View larger version (33K):
[in this window]
[in a new window]

  		FIG. 2. Immunofluorescence microscopy of frozen sections stained with fibronectin and type IV collagen antibody (40x magnification). A and B: Control mice with anti-fibronectin. C and D: FVBdb/db mice with anti-fibronectin. E and F: Control mice with anti–collagen IV. G and H: FVBdb/db mice with anti–collagen IV. There is increased staining in both the glomeruli and tubulointerstitial cells. n = 4 mice in each experimental group.

 

Figure 3
View larger version (47K):
[in this window]
[in a new window]

  		FIG. 3. Electron microscopy of glomeruli (11,500x magnification). A: Control. B: FVBdb/db mice. Capillary lumen (CL), urinary space (US), podocyte foot process (FP), and glomerular basement membrane (GBM) are denoted. C and D: Measurements of glomerular basement membrane thickness (D) and foot process length (C). {square}, control mice; {blacksquare}, FVBdb/db mice. Data are the means ± SE, n = 4 mice in each experimental group.

 
FVBdb/db mice have increased expression of growth factors.
The glomerulosclerosis, tubulointerstitial fibrosis, and proteinuria of FVBdb/db mice is associated with significant increases in renal mRNA abundance of TGF-ß, PAI-1, and VEGF (Table 2).


View this table:
[in this window]
[in a new window]

  		TABLE 2 Real-time PCR data for growth factors

 
FVBdb/db mice have increased lipid deposits in kidney.
There is very strong staining of oil red O in the glomeruli of FVBdb/db (Fig. 4B) and almost no staining in lean mice (Fig. 4A). Adipophilin (ADRP) is a marker of lipid droplets. Immunofluorescence microscopy reveals typical lipid droplets as ring-shaped red dots in the tubules of FVBdb/db mice (Fig. 4D). In contrast, there are almost no lipid droplets in the lean control mice (Fig. 4C). In addition, Western blot clearly shows a 65% increase of ADRP protein expression in FVBdb/db mice (Fig. 4E). These data strongly indicate that there are excessive amounts of lipid deposits in the kidneys of FVBdb/db mice.


Figure 4
View larger version (76K):
[in this window]
[in a new window]

  		FIG. 4. A and B: Oil red O staining of frozen kidney sections (glomeruli; 40x magnification) for control mice (A) and FVBdb/db mice (B). C and D: Adipophilin (ADRP) immunofluorescence microscopy (tubules) for control mice (C) and FVBdb/db mice (D) (40x magnification). Nuclei are blue from 4',6-diamidino-2-phenylindole stain. E: Western blot and densitometric quantification of ADRP. Blot represents eight samples from each group; relative densitometry units are used for comparison. {square}, control mice; {blacksquare}, FVBdb/db mice. Data are the means ± SE.

 
FVBdb/db mice have increased nuclear SREBP-1 and -2 protein abundance.
In our previous study in animals with type 1 diabetes, we found that SREBPs play a major role in regulating renal lipid metabolism. In this study we found significant increases in nuclear SREBP-1 and -2 abundance in the kidneys of FVBdb/db mice (Figs. 5A and B).


Figure 5
View larger version (11K):
[in this window]
[in a new window]

  		FIG. 5. Western blot and densitometric quantification of SREBP-1 (A) and SREBP-2 (B) protein in kidney nuclear extracts. Blot represents eight samples from each group; relative densitometry units are used for comparison. {square}, control mice; {blacksquare}, FVBdb/db mice. Data are the means ± SE.

 
FVBdb/db mice have increased renal expression of genes regulating triglyceride and cholesterol metabolism.
For FVBdb/db mice, the increase in SREBP-1 protein abundance is paralleled by significant increases in the mRNA abundance of two SREBP-1–activated enzymes that mediate fatty acid synthesis, ACC, and FAS (Table 3). The increase in fatty acid synthesis is associated with a significant increase in renal triglyceride content (Table 1). Because triglyceride accumulation can also be mediated by decreased fatty acid oxidation, we also determined the renal abundance of PPAR-{alpha} and its target enzyme ACO, important mediators of fatty acid oxidation. There were no statistically significant increases in PPAR-{alpha} and ACO (Table 3), indicating that the increase in renal triglyceride content is not mediated by decreased fatty acid oxidation.


View this table:
[in this window]
[in a new window]

  		TABLE 3 Real-time PCR data for lipid metabolism pathways

 
Similarly, the increase in SREBP-2 protein abundance is paralleled by significant increases in the mRNA abundances of two SREBP-2–activated genes that mediate cholesterol synthesis (HMG-CoA reductase) and cholesterol uptake (LDL receptor) (Table 3). These increases are paralleled by a significant increase in renal cholesterol content (Table 1). Because cholesterol accumulation can also be mediated by decreased cholesterol efflux, we determined the renal abundance of LXR and ABCA-1. There were actually significant increases in LXR and ABCA-1 mRNA abundance (Table 3). Thus, the increase in renal cholesterol content of FVBdb/db mice occurs despite a probable increase in renal cholesterol efflux.


   DISCUSSION
TOP
 ABSTRACT
 RESEARCH DESIGN AND METHODS
 RESULTS
 DISCUSSION
REFERENCES
 
There are well-known changes in diabetes-related renal function and structure, including glomerulosclerosis, proteinuria, and decline in glomerular filtration rate. Several hormonal and metabolic factors, including angiotensin II (34), TGF-ß (35), VEGF (36), oxidative stress (37), advanced glycation end products (38), and nitric oxide (39), have been shown to modulate diabetes-related renal disease in rodents. In addition, renal accumulation of lipids has also been proposed to play a role in the pathogenesis of diabetic nephropathy (6–7). Our previous study in streptozotocin-induced type 1 diabetes has shown that altered lipid metabolism plays an important role in the development of diabetic nephropathy. Furthermore, we were able to demonstrate that SREBPs are the key factors linking nephropathy to the dysregulation of lipid metabolism (4).

In FVBdb/db mice, a type 2 diabetes animal model, we found evidence of diabetic nephropathy, such as increased urine albumin-to-creatinine ratio, increased matrix protein, mesangial expansion, thickening of the glomerular basement membrane, effacement of podocyte foot processes, significant glomerulosclerosis, tubulointerstitial fibrosis, and proteinuria. These renal functional and structural changes are associated with increased mRNA abundance of TGF-ß, PAI-1, and VEGF, growth factors that have been shown to play an important role in mediating glomerulosclerosis and proteinuria (35,36,40).

A novel finding of our study is that we found excessive amounts of lipid deposits in the diabetic kidney, as shown by increased oil red O staining, and the presence of lipid bodies, as shown by ADRP immunofluorescence microscopy and ADRP protein levels, using Western blotting. These changes correspond to highly elevated kidney cholesterol and triglyceride content.

We have found that the increases in renal triglyceride and cholesterol content are most likely mediated by increased nuclear protein levels and transcriptional activities of SREBP-1 and -2. We found that in FVBdb/db mice, increased levels of SREBP-1 protein is associated with increased mRNA abundance of ACC and FAS, two key enzymes that mediate increased fatty acid synthesis, which results in increased triglyceride synthesis and accumulation (10,13). Because we found no significant changes in the mRNA abundance of PPAR-{alpha} and its target enzyme, ACO, it is unlikely that decreases in fatty acid oxidation could be responsible for the triglyceride accumulation.

In addition, in FVBdb/db mice, increased levels of SREBP-2 protein is associated with increased mRNA abundance of HMG-CoA reductase, a key enzyme that mediates cholesterol synthesis, and LDL receptor, which mediates cholesterol uptake. These alterations in gene expression would result in a significant increase in renal cholesterol content. Because cholesterol accumulation can also be mediated by decreased cholesterol efflux, we also determined the renal abundance of LXR and ABCA-1, important mediators of cholesterol efflux (41,42). There were actually significant increases in LXR and ABCA-1 mRNA abundance. Thus, the accumulation of renal cholesterol in the FVBdb/db mouse occurs, despite probable increases in cholesterol efflux.

Previous studies in renal mesangial and tubular cells grown in culture have shown that incubation of these cells with LDL or VLDL induces upregulation of growth factors, including TGF-ß (43), PAI-1 (44), and accumulation of extracellular matrix proteins (45), indicating a direct role for lipids in activating the mediators of glomerulosclerosis. Recent studies indicate that VEGF is actively involved in the pathogenesis of diabetic nephropathy (36,46,47). Results from our study do confirm those previous findings and support the theory that altered lipid accumulation is contributing to the development of diabetic nephropathy.

In addition, our study in SREBP-1a transgenic mice suggests that increased renal triglyceride and cholesterol accumulation mediated by increased renal expression of SREBPs do play a critical role in the pathogenesis of glomerulosclerosis and proteinuria. In SREBP-1a transgenic mice, in the absence of any increases in serum glucose, triglyceride, or cholesterol level, we reported that increased renal accumulation of triglycerides results in increased renal abundance of TGF-ß, VEGF, type IV collagen, and fibronectin, resulting in glomerulosclerosis and proteinuria (4).

In conclusion, our results indicate that in FVBdb/db mice that are obese and have type 2 diabetes, glomerulosclerosis, tubulointerstitial fibrosis, and proteinuria are associated with marked alterations in renal lipid metabolism mediated by increased expression of SREBPs, resulting in renal accumulation of lipid bodies, triglycerides, and cholesterol. The increased expression of genes responsible for triglycerides and cholesterol metabolism indicates that increased synthesis rather than decreased oxidation or decreased efflux is the mechanism for triglyceride and cholesterol accumulation. We propose that abnormalities of renal lipid metabolism play an important role in the pathogenesis of diabetic nephropathy.


   ACKNOWLEDGMENTS
 
These studies were supported by grants to M.L. (National Institutes of Health [NIH] 5R01 DK062209-02, NIH 7RO3 AG20361-2, and Juvenile Diabetes Research Foundation 1-2003-108), Z.W. (NIH GI Training Grant T32 DK-07038-29), J.M. (NIH 5RO1 HD045965), and S.C. (DK63306).

Received for publication January 25, 2005 and accepted in revised form April 6, 2005


   REFERENCES
TOP
 ABSTRACT
 RESEARCH DESIGN AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Hsu C, Bates D, Kuperman G, Curhan G: Diabetes, hemoglobin A (1c) cholesterol and the risk of moderate chronic renal insufficiency in an ambulatory population. Am J Kidney Dis 36:272–281, 2001
  2. Keane WF: The role of lipids in renal disease: future challenges. Kidney Int Suppl 75:S27–S31, 2000[Medline]
  3. Oda H, Keane WF: Lipids in progression of renal disease. Kidney Int Suppl 62:S36–S38, 1997[Medline]
  4. Sun L, Halaihel N, Zhang W, Rogers T, Levi M: Role of sterol regulatory element-binding protein 1 in regulation of renal lipid metabolism and glomerulosclerosis in diabetes mellitus. J Biol Chem 277:18919–18927, 2002[Abstract/Free Full Text]
  5. Kimmelstiel P, Wilson C: Intracapillary lesions in the glomeruli of the kidney. Am J Pathol 12:83–98, 1936
  6. Guijarro C, Kasiske BL, Kim Y, O’Donnell MP, Lee HS, Keane WF: Early glomerular changes in rats with dietary-induced hypercholesterolemia. Am J Kidney Dis 26:152–161, 1995[Medline]
  7. Lee HS, Lee JS, Koh HI, Ko KW: Intraglomerular lipid deposition in routine biopsies. Clin Nephrol 36:67–75, 1991[Medline]
  8. Brown MS, Goldstein JL: The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor. Cell 89:331–340, 1997[Medline]
  9. Horton JD, Shimomura I: Sterol regulatory element-binding proteins: activators of cholesterol and fatty acid biosynthesis. Curr Opin Lipidol 10:143–150, 1999[Medline]
  10. Browning JD, Horton JD: Molecular mediators of hepatic steatosis and liver injury. J Clin Invest 114:147–152, 2004[Medline]
  11. Rawson RB: Control of lipid metabolism by regulated intramembrane proteolysis of sterol regulatory element binding proteins (SREBPs). Biochem Soc Symp 70:221–231, 2003
  12. Shimano H, Horton JD, Hammer RE, Shimomura I, Brown MS, Goldstein JL: Overproduction of cholesterol and fatty acids causes massive liver enlargement in transgenic mice expressing truncated SREBP-1a. J Clin Invest 98:1575–1584, 1996[Medline]
  13. Horton JD, Shah NA, Warrington JA, Anderson NN, Park SW, Brown MS, Goldstein JL: Combined analysis of oligonucleotide microarray data from transgenic and knockout mice identifies direct SREBP target genes. Proc Natl Acad Sci U S A 100:12027–12032, 2003[Abstract/Free Full Text]
  14. Sessa A, Meroni M, Battini G, Righetti M, Maglio A, Tosoni A, Nebuloni M, Vago G, Giordano F: Renal involvement in Anderson-Fabry disease. J Nephrol 16:310–313, 2003[Medline]
  15. Zhu X, Herzenberg AM, Eskandarian M, Maguire GF, Scholey JW, Connelly PW, Ng DS: A novel in vivo lecithin-cholesterol acyltransferase (LCAT)-deficient mouse expressing predominantly LpX is associated with spontaneous glomerulopathy. Am J Pathol 165:1269–1278, 2004[Abstract/Free Full Text]
  16. Yokoyama K, Hayashi H, Hinoshita F, Yamada A, Suzuki Y, Ogura Y, Kanbayashi H, Endo Y, Kawai T, Hara M: Renal lesion of type Ia glycogen storage disease: the glomerular size and renal localization of apolipoprotein. Nephron 70:348–352, 1995[Medline]
  17. Javor ED, Moran SA, Young JR, Cochran EK, DePaoli AM, Oral EA, Turman MA, Blackett PR, Savage DB, O’Rahilly S, Balow JE, Gorden P: Proteinuric nephropathy in acquired and congenital generalized lipodystrophy: baseline characteristics and course during recombinant leptin therapy. J Clin Endocrinol Metab 89:3199–3207, 2004[Abstract/Free Full Text]
  18. Rao A, D’Amico S, Balasubramanyam A, Maldonado M: Fenofibrate is effective in treating hypertriglyceridemia associated with HIV lipodystrophy. Am J Med Sci 327:315–318, 2004[Medline]
  19. Aiello RJ, Brees D, Francone OL: ABCA1-deficient mice: insights into the role of monocyte lipid efflux in HDL formation and inflammation. Arterioscler Thromb Vasc Biol 23:972–980, 2003[Abstract/Free Full Text]
  20. Christiansen-Weber TA, Voland JR, Wu Y, Ngo K, Roland BL, Nguyen S, Peterson PA, Fung-Leung WP: Functional loss of ABCA1 in mice causes severe placental malformation, aberrant lipid distribution, and kidney glomerulonephritis as well as high-density lipoprotein cholesterol deficiency. Am J Pathol 157:1017–1029, 2000[Abstract/Free Full Text]
  21. Lassila M, Seah KK, Allen TJ, Thallas V, Thomas MC, Candido R, Burns WC, Forbes JM, Calkin AC, Cooper ME, Jandeleit-Dahm KA: Accelerated nephropathy in diabetic apolipoprotein e-knockout mouse: role of advanced glycation end products. J Am Soc Nephrol 15:2125–2138, 2004[Abstract/Free Full Text]
  22. Bruneval P, Bariety J, Belair MF, Mandet C, Heudes D, Nicoletti A: Mesangial expansion associated with glomerular endothelial cell activation and macrophage recruitment is developing in hyperlipidemic apoE null mice. Nephrol Dial Transplant 17:2099–2107, 2002[Abstract/Free Full Text]
  23. Crook ED, Thallapureddy A, Migdal S, Flack JM, Greene EL, Salahudeen A, Tucker JK, Taylor HA Jr: Lipid abnormalities and renal disease: is dyslipidemia a predictor of progression of renal disease? Am J Med Sci 325:340–348, 2003[Medline]
  24. Abrass CK: Cellular lipid metabolism and the role of lipids in progressive renal disease. Am J Nephrol 24:46–53, 2004[Medline]
  25. Fried LF, Orchard TJ, Kasiske BL: Effect of lipid reduction on the progression of renal disease: a meta-analysis. Kidney Int 59:260–269, 2001[Medline]
  26. Nakao T, Yoshino M, Matsumoto H, Okada T, Han M, Hidaka H, Shino T, Yamada C, Nagaoka Y, Miyahara T: Low-density lipoprotein apheresis retards the progression of hyperlipidemic overt diabetic nephropathy. Kidney Int Suppl 71:S206–S209, 1999[Medline]
  27. Bianchi S, Bigazzi R, Caiazza A, Campese VM: A controlled, prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease. Am J Kidney Dis 41:565–570, 2003[Medline]
  28. Chua S Jr, Liu SM, Li Q, Yang L, Thassanapaff VT, Fisher P: Differential beta cell responses to hyperglycaemia and insulin resistance in two novel congenic strains of diabetes (FVB- Lepr (db)) and obese (DBA- Lep (ob)) mice. Diabetologia 45:976–990, 2002[Medline]
  29. Morooka H, Bonventre JV, Pombo CM, Kyriakis JM, Force T: Ischemia and reperfusion enhance ATF-2 and c-Jun binding to cAMP response elements and to an AP-1 binding site from the c-jun promoter. J Biol Chem 270:30084–30092, 1995[Abstract/Free Full Text]
  30. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ: Protein measurement with the Folin phenol reagent. J Biol Chem 193:265–275, 1951[Free Full Text]
  31. Bligh EG, Dyer WJ: A rapid method of total lipid extraction and purification. Can J Biochem Physiol 37:911–917, 1959
  32. McManaman JL, Palmer CA, Wright RM, Neville MC: Functional regulation of xanthine oxidoreductase expression in the mouse mammary gland: evidence of a role in lipid secretion. J Physiol 545:567–579, 2002[Abstract/Free Full Text]
  33. Heid HW, Moll R, Schwetlick I, Rackwitz HR, Keenan TW: Adipophilin is a specific marker of lipid accumulation in diverse cell types and diseases. Cell Tissue Res 294:309–321, 1998[Medline]
  34. Nicholas SB, Mauer M, Basgen JM, Aguiniga E, Chon Y: Effect of angiotensin II on glomerular structure in streptozotocin-induced diabetic rats. Am J Nephrol 24:549–556, 2004[Medline]
  35. Sharma R, Khanna A, Sharma M, Savin VJ: Transforming growth factor-beta1 increases albumin permeability of isolated rat glomeruli via hydroxyl radicals. Kidney Int 58:131–136, 2000[Medline]
  36. Cha DR, Kang YS, Han SY, Jee YH, Han KH, Han JY, Kim YS, Kim NH: Vascular endothelial growth factor is increased during early stage of diabetic nephropathy in type II diabetic rats. J Endocrinol 183:183–194, 2004[Abstract/Free Full Text]
  37. Pillarisetti S, Saxena U: Role of oxidative stress and inflammation in the origin of type 2 diabetes: a paradigm shift. Expert Opin Ther Targets 8:401–408, 2004[Medline]
  38. Yamagishi S, Takeuchi M, Inagaki Y, Nakamura K, Imaizumi T: Role of advanced glycation end products (AGEs) and their receptor (RAGE) in the pathogenesis of diabetic microangiopathy. Int J Clin Pharmacol Res 23:129–134, 2003[Medline]
  39. Erdely A, Freshour G, Maddox DA, Olson JL, Samsell L, Baylis C: Renal disease in rats with type 2 diabetes is associated with decreased renal nitric oxide production. Diabetologia 47:1672–1676, 2004[Medline]
  40. Paueksakon P, Revelo MP, Ma LJ, Marcantoni C, Fogo AB: Microangiopathic injury and augmented PAI-1 in human diabetic nephropathy. Kidney Int 61:2142–2148, 2002[Medline]
  41. Tontonoz P, Mangelsdorf DJ: Liver X receptor signaling pathways in cardiovascular disease. Mol Endocrinol 17:985–993, 2003[Abstract/Free Full Text]
  42. Attie AD, Kastelein JP, Hayden MR: Pivotal role of ABCA1 in reverse cholesterol transport influencing HDL levels and susceptibility to atherosclerosis. J Lipid Res 42:1717–1726, 2001[Abstract/Free Full Text]
  43. Okada M, Takemura T, Yanagida H, Yoshioka K: Response of mesangial cells to low-density lipoprotein and angiotensin II in diabetic (OLETF) rats. Kidney Int 61:113–124, 2002[Medline]
  44. Song CY, Kim BC, Hong HK, Kim BK, Kim YS, Lee HS: Biphasic regulation of plasminogen activator/inhibitor by LDL in mesangial cells. Am J Physiol Renal Physiol 283:F423–F430, 2002[Abstract/Free Full Text]
  45. Lee HS: Oxidized LDL, glomerular mesangial cells and collagen. Diabetes Res Clin Pract 45:117–122, 1999[Medline]
  46. Kakizawa H, Itoh Y, Imamura S, Matsumoto T, Ishiwata Y, Ono Y, Yamamoto K, Kato T, Hayakawa N, Oda N, Goto Y, Goto Y, Nagasaka A, Senda T, Itoh M: Possible role of VEGF in the progression of kidney disease in streptozotocin (STZ)-induced diabetic rats: effects of an ACE inhibitor and an angiotensin II receptor antagonist. Horm Metab Res 36:458–464, 2004[Medline]
  47. Flyvbjerg A, Dagnaes-Hansen F, De Vriese AS, Schrijvers BF, Tilton RG, Rasch R: Amelioration of long-term renal changes in obese type 2 diabetic mice by a neutralizing vascular endothelial growth factor antibody. Diabetes 51:3090–3094, 2002[Abstract/Free Full Text]

Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 Am. J. Physiol. Renal Physiol.Home page
K. A. Griffin, M. Abu-Naser, I. Abu-Amarah, M. Picken, G. A. Williamson, and A. K. Bidani
Dynamic blood pressure load and nephropathy in the ZSF1 (fa/facp) model of type 2 diabetes
Am J Physiol Renal Physiol, November 1, 2007; 293(5): F1605 - F1613.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
T. Jiang, X. X. Wang, P. Scherzer, P. Wilson, J. Tallman, H. Takahashi, J. Li, M. Iwahashi, E. Sutherland, L. Arend, et al.
Farnesoid X Receptor Modulates Renal Lipid Metabolism, Fibrosis, and Diabetic Nephropathy
Diabetes, October 1, 2007; 56(10): 2485 - 2493.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
S. Kume, T. Uzu, S.-i. Araki, T. Sugimoto, K. Isshiki, M. Chin-Kanasaki, M. Sakaguchi, N. Kubota, Y. Terauchi, T. Kadowaki, et al.
Role of Altered Renal Lipid Metabolism in the Development of Renal Injury Induced by a High-Fat Diet
J. Am. Soc. Nephrol., October 1, 2007; 18(10): 2715 - 2723.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Renal Physiol.Home page
J. Dominguez, P. Wu, C. S. Packer, C. Temm, and K. J. Kelly
Lipotoxic and inflammatory phenotypes in rats with uncontrolled metabolic syndrome and nephropathy
Am J Physiol Renal Physiol, September 1, 2007; 293(3): F670 - F679.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
H. Boulanger, R. Mansouri, J. F. Gautier, and D. Glotz
Are peroxisome proliferator-activated receptors new therapeutic targets in diabetic and non-diabetic nephropathies?
Nephrol. Dial. Transplant., October 1, 2006; 21(10): 2696 - 2702.
[Full Text] [PDF]

Home page
 DiabetesHome page
G. Proctor, T. Jiang, M. Iwahashi, Z. Wang, J. Li, and M. Levi
Regulation of Renal Fatty Acid and Cholesterol Metabolism, Inflammation, and Fibrosis in Akita and OVE26 Mice With Type 1 Diabetes
Diabetes, September 1, 2006; 55(9): 2502 - 2509.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Renal Physiol.Home page
W. E. Rodriguez, N. Tyagi, I. G. Joshua, J. C. Passmore, J. T. Fleming, J. C. Falcone, and S. C. Tyagi
Pioglitazone mitigates renal glomerular vascular changes in high-fat, high-calorie-induced type 2 diabetes mellitus
Am J Physiol Renal Physiol, September 1, 2006; 291(3): F694 - F701.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wang, Z.
Right arrow Articles by Levi, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wang, Z.
Right arrow Articles by Levi, M.
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum